Three patients admitted to the intensive care unit after multiple injury were observed to suffer episodes of adrenocortical insufficiency suggested by clinical manifestations and confirmed by appropriately low cortisol concentrations. This prompted a prospective study of pituitary-adrenocortical function in six multiply injured patients, three ofwhom showed evidence ofadrenocortical suppression. The only factor common to the six patients with abnormally low adrenocortical function was an association between periods ofadrenocortical suppression and intravenous infusion of etomidate; when the drug was stopped adrenocortical function was restored, and renewed administration of the drug caused further inhibition. Etomidate infusions lasting only six hours were found to cause low, flat responses to short tetracosactrin tests and grossly raised plasma concentrations of adrenocorticotrophic hormone, suggesting direct suppression of the adrenal cortex. Median plasma cortisol concentrations measured at 0900 were significantly lower and median plasma concentrations of adrenocorticotrophic hormone measured at 0900 were significantly higher in the three patients studied prospectively who were receiving etomidate infusions compared with the three patients who did not receive etomidate (p= 005).
adrenocortical function in multiply injured patients admitted to the unit. This study was terminated after reports indicated increased mortality in patients treated with etomidate infusions2 and incriminated adrenocortical suppression as a possible aetiological factor. This prompted us to examine retrospectively our records of etomidate infusion and to correlate this treatment with changes in adrenocortical function in the patients studied.
Patients and methods
During 1982 three multiply injured patients in our intensive care unit developed clinical features of Addisonian crisis associated with abnormally low plasma cortisol concentrations. We therefore studied prospectively six further patients admitted after traumatic injury, three of whom received etomidate. Plasma concentrations of adrenocorticotrophic hormone and cortisol were determined daily at 0900 and tests were performed using a stimulus of 0-25 mg tetracosactrin (Synacthen) intravenously with measurement of plasma cortisol concentration at 30 and 60 minutes. In the six patients studied prospectively the median plasma concentrations of adrenocorticotrophic hormone and cortisol measured at 0900 in the three patients who received etomidate were compared with those in the three patients who did not (Mann-Whitney U test; p-0 05 was taken as denoting a significant difference). Injury severity scores of the patients were determined by the method of Baker et al.3 In patients receiving etomidate the infusion rate was altered according to individual requirements, using a modified Glasgow coma scale.4 Some patients required additional muscle relaxants to ensure efficient ventilation, and in these the minimum rate of infusion of etomidate to ensure sedation was given, based on the previous requirement.
Plasma adrenocorticotrophic hormone concentration was measured by immunoassay (kit IM66, Amersham International) (between batch coefficients of variation were 108°' at a mean concentration of 50 ng/l and 1700 at a mean concentration of 900 ng/l; normal range 0-100 ng/l). Plasma cortisol concentration was estimated by immunoassay of 125I labelled cortisol using solid phase antisera raised against cortisol-30-carboxymethyloxime; between batch coefficients of variation were 130o at a mean concentration of 100 nmol/l (3 6 jsg/100 ml) and 9°o at a mean concentration of 800 nmol/l (29 ,ug/100 ml) (normal concentration at 0900 > 250 nmol/l ( > 9 1 ,ug/100 ml)).
Results

PATIENTS STUDIED RETROSPECTIVELY
The three patients in this group showed low plasma cortisol concentrations in the presence of clinical features suggesting the possibility of an Addisonian crisis; all three patients received infusions of etomidate concurrently with these episodes (table I) . Two patients (cases 1 and 2) received intravenous methylprednisolone 2-4 g on the day of admission. The remaining patient (case 3) did not receive methylprednisolone, but intravenous administration of hydrocortisone 100 mg after the short tetracosactrin test on day 20 led to a prompt increase in arterial blood pressure (systolic arterial blood pressure increased from 95 to 120 mm Hg within an hour of injection of hydrocortisone) and reversal of oliguria. In all three patients adrenocortical function was restored after the etomidate infusion was stopped.
PATIENTS STUDIED PROSPECTIVELY
Of the six patients studied prospectively, only three received etomidate infusions during their admlission. Two patients (cases 4 and 5 (figure)) had abnormally low plasma cortisol concentrations and grossly raised plasma adrenocorticotrophic hormone concentrations on the day of admission within six hours after receiving etomidate infusions. when at 0900, 60 hours after administration of methylprednisolone 2 g intravenously, the plasma cortisol concentration was 100 nmol/l (3-6 ,ug/100 ml) and plasma adrenocorticotrophic hormone concentration was 110 ng/l; 24 hours later the response to a short tetracosactrin test was normal (260 nmol/l (9-4 ,ug/100 ml) increasing to 860 nmol/l (31-0 Itg/100 ml) one hour after administration of tetracosactrin).
This solitary low plasma cortisol concentration was attributed to the effect of methylprednisolone in suppressing the hypothalamic-pituitary axis.5
Median plasma cortisol concentrations at 0900 were significantly lower in the three patients receiving etom-iidate than in the three patients not receiving it (table II; p =005). Similarly, median plasma concentrations of adrenocorticotrophic hormone were significantly higher in those patients receiving etomidate than in those not (table II; p 005). To exclude the effect of methylprednisolone in suppressing the hypothalamic-pituitary axis4 we analysed these data excluding the results of assays performed within three days after administration of methylprednisolone (table III) ; the disparity in the plasma concentrations of cortisol and adrenocorticotrophic hormone between the two groups of patients persisted (p = 005). Conversion: SI to traditional units-Cortisol: 1 nmol/lI 0 036 ,g/100 ml.
EFFECTS OF OTHER DRUGS
All nine patients studied received many other drugs during their admission, particularly antibiotics, opiates, benzodiazepines, histamine H, receptor antagonists, and beta adrenoceptor agonists, but etomidate was the only agent whose administration was related invariably to suppression of the plasma cortisol concentration and an increase in the plasma adrenocorticotrophic hormone concentration. All other drugs that were prescribed during the episodes of adrenocortical suppression were also administered during periods of normal pituitaryadrenocortical function, either in the same patient or in patients who never showed abnormalities of the pituitary-adrenocortical axis.
Discussion
These results indicate that adrenocortical suppression may occur in a group of patients previously suggested not to be at risk." The original three patients in whom adrenocortical suppression was observed were found on review to have received etomidate infusions that were related temporally to the episodes of adrenocortical suppression, and in one case prompt reversal of symptomatic hypotension and oliguria was seen after intravenous injection of hydrocortisone 100 mg. Normal adrenocortical function was restored after the etomidate infusion was stopped in these three patients.
Among the patients studied prospectively only those who were receiving etomidate infusions suffered adrenocortical suppression, while those sedated with opiates and benzodiazepines showed plasma cortisol concentrations appropriate for multiply injured patients.6 Plasma cortisol concentrations recovered when etomidate was stopped and were suppressed further when it was started again. The suppression of plasma glucocorticoid concentrations occurred within six hours of the start of etomidate infusion in two patients; this time course was comparable with the acute effect of etomidate injection into rodents7 and suggested that the original three patients may have suffered adrenocortical suppression for several days before developing symptoms of hypotension or hyponatraemia and hyperkalaemia. The concurrence of a low, flat response to the short tetracosactrin test and grossly raised plasma concentrations of adrenocorticotrophic hormone strongly suggested a direct effect of etomidate in suppressing either synthesis or secretion of cortisol by the adrenal gland, rather than a central effect as suggested by its action mimicking that of y-aminobutyric acid.7
In this group of patients maintenance of arterial blood pressure was not critically dependent on normal adrenocortical function, which may explain previous reports of the stability of cardiovascular function when etomidate is used as an induction agent in anaesthesia.8 Other mechanisms that maintain arterial blood pressure, such as angiotensin II, may be important in adrenocortical suppression. 9 Only one of the patients in this study died, and the study was terminated on receipt of information from the Committee on Safety of Medicines on reports of increased mortality in injured patients receiving long term infusion of etomidate2; thus the data are insufficient to show any effect on mortality.
This effect of etomidate merits further study as it raises the possibility that similar compounds might have therapeutic potential in controlling secretion of steroids.
